Title:Structural Proteomics: Detection of Neurodegenerative Protein Modifications
Volume: 22
Issue: 9
Author(s): Mallika Khurana, Syed Obaidur Rahman, Shivani Agarwal, Md. Sayeed Akhtar, Mohammed S. Aldughaim, Faheem Hyder Pottoo*Abul Kalam Najmi*
Affiliation:
- Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Damman 31441,Saudi Arabia
- Pharmaceutical Medicine, Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062,India
Keywords:
Cross-linking mass spectrometry, neurodegenerative diseases, neuroproteomics, hydrogen deuterium trade mass spectrometry, cerebrospinal fluid, brain tissue sample.
Abstract: For decades now, neurodegenerative disorders have been explored, but their prompt detection
is still very strenuous due to the complexity of the brain. This entails the demand for identification
and development of clinical biomarkers in order to comply with the criteria of precision,
specificity and repeatability. The use of rapidly evolving technologies such as Mass Spectrometry
(MS) in proteomics has opened new ways to speed up the discovery of biomarkers, both for diagnostic
and prognostic purposes. The wide range of possibilities for the detection of differentially expressed
proteins in specific diseases has been opened by several novel proteomic techniques such
as cross-linking mass spectrometry, hydrogen-deuterium exchange mass spectrometry, protein foot
printing and more. Still, much research is required to give a deep insight into the complex system
of the brain and its related disorders for unraveling prognostic and diagnostic biomarkers, which
can be used to either enhance a certain function of our brain or to cure a particular disease/disorder.
This review summarizes the latest developments in neuroproteomics and analyzes existing and potential
directions for the discovery of biomarkers for neurodegenerative diseases.
